Effect of the oXiris membrane on microcirculation after cardiac surgery under cardiopulmonary bypass: study protocol for a randomised controlled trial (OXICARD Study)

Osama Abou-Abar, Pierre Huette, Guillaume Haye, Mathieu Guilbart, Gilles Touati, Momar Diouf, Christophe Beyls, Herve Dupont, Yazine Mahjoub

ABSTRACT

Introduction Cytokine storm and endotoxin release during cardiac surgery with cardiopulmonary bypass (CPB) have been related to vasoplegic shock and organ dysfunction. We hypothesised that early (during CPB) cytokine adsorption with oXiris membrane for patients at high risk of inflammatory syndrome following cardiac surgery may improve microcirculation, endothelial function and outcomes.

Methods and analysis The Oxicard trial is a prospective, monocentric trial, randomising 70 patients scheduled for cardiac surgery. The inclusion criterion is patients aged more than 18 years undergoing elective cardiac surgery under CPB with an expected CPB time >90 min (double valve replacement or valve replacement plus coronary artery bypass graft). Patients will be allocated to the intervention group (n=35) or the control group (n=35). In the intervention group, oXiris membrane will be used on the Prismaflex device (Baxter) at blood pump flow of 450 mL/min during cardiac surgery under CPB. In the control group, cardiac surgery under CPB will be conducted as usual without oXiris membrane. An intention-to-treat analysis will be performed. The primary endpoint will be the microcirculatory flow index measured by sublingual microcirculation device at day 1 following cardiac surgery. The secondary endpoints will be other microcirculation variables at CPB end, 6 hours after CPB, at day 1 and at day 2. We also aim to evaluate the occurrence of major cardiovascular and cerebral events (eg, myocardial infarction, stroke, ischaemic mesenteric, resuscitated cardiac arrest, acute kidney injury) within the first 30 days. Cumulative catecholamine use, intensive care unit length of stay, endothelium glycocalyx shedding parameters (syndecan-1, heparan-sulfate and hyaluronic acid), inflammatory cytokines (tumour necrosis factor (TNF) alpha, interleukin 1 (IL1) beta, IL 10, IL 6, lipopolysaccharide, endothelin) and endothelial permeability biomarkers (angiopoietin 1, angiopoietin 2, Tie2 soluble receptor and Vascular Endothelial Growth Factor (VEGF) will also be evaluated.

Ethics and dissemination Ethical approval has been obtained from the Institutional Review Board of the University Hospital of Amiens (registration number ID RDB: NCT04201119).

Strengths and limitations of this study

- The trial will be a prospective, monocentric, randomised trial and will include 70 patients scheduled for cardiac surgery.
- We will include patients undergoing elective cardiac surgery under cardiopulmonary bypass (CPB) with an expected CPB time >90 min.
- The intervention that is being investigated is oXiris membrane use during cardiac surgery under CPB.
- The primary endpoint will be the microcirculatory flow index measured by sublingual microcirculation device at day 1 following cardiac surgery.
- The secondary endpoints will include major outcomes within the first 30 days, endothelium glycocalyx shedding variables, inflammatory cytokines and endothelial permeability biomarkers.

INTRODUCTION

A ‘sepsis-like syndrome’ is often observed in postoperative cardiac surgery under cardiopulmonary bypass (CPB), especially when CPB is over 90 min (double valve replacement or valve replacement plus coronary arterial bypass graft (CABG)).

This condition is due to microcirculation disturbances induced by endothelial dysfunction. Indeed, extracorporeal circulation, associated with aortic clamping, induces changes in the blood circulation with a so-called continuous circulation (unlike the usual pulsed circulation), leading to a heterogeneity of organ perfusion. The associated vasoplectic syndrome in postoperative cardiac surgery is due to acute circulatory failure.
defined by persistent low blood pressure, requiring treatment with vasopressors. From a pathophysiological point of view, SV is the result of a complex inflammatory cascade whose origin is multifactorial. This proinflammatory state activates complement, platelets and leukocytes which release vasoactive substances. Following CPB, impaired microcirculation is still common and can lead to true organ failure by decreasing oxygen delivery to tissues. Impaired microcirculation after bypass surgery has been well demonstrated with a decrease in microcirculatory flow to the lateral margin of the tongue. The use of sidestream or incident dark field/orthogonal polarised microscopy remains the reference method to clinically assess microcirculation. The most easily accessible site at the patient’s bedside is the microcirculation of the sublingual mucosa. This proinflammatory state can be modulated with the removal of cytokines. The oXiris (Baxter, Illinois, USA) membrane is an AN-69 membrane, surface-treated with polyethylenimine and grafted with heparin. This property allows the adsorption of inflammatory cytokines and lipopolysaccharide (LPS). The accepted indication is sepsis or septic shock requiring renal replacement therapy (RRT). In cardiac surgery, there are no sufficient clinical data to recommend the use of the oXiris membrane to reduce postoperative inflammatory syndrome. Some studies have demonstrated the feasibility of using the oXiris membrane during cardiac surgery with CPB with effective removal of inflammatory cytokines. However, to date, no studies have established the beneficial effect of cytokine removal on microcirculatory variables.

We hypothesised that the early use (during CPB) of cytokine adsorption with the oXiris membrane in patients at high risk of inflammatory syndrome following cardiac surgery may improve microcirculation and, hence, clinical outcomes.

METHODS AND ANALYSIS

Study design

This is a monocentric, prospective, randomised study.

Study population

The inclusion criteria are as follows:

- Patients aged more than 18 years old.
- Elective cardiac surgery under CPB with an expected CPB time >90 min (double valve replacement or valve replacement plus coronary arterial bypass graft (CABG)).
- Written informed consent from patient or next of kin.

The non-inclusion criteria are as follows:

- Missing informed consent.
- Patient under 18 years old.
- Planned hypothermia <32°C during CPB.
- Emergency surgery.
- Acute infective endocarditis.
- Immunosuppressive treatment or steroids (prednisone >0.5 mg/kg/day or equivalent).

- AIDS with a CD4 count of <200/mm³.
- Autoimmune disorder.
- Transplant recipient.
- Advances chronic kidney disease (CKD 4 or 5).
- RRT in the last 90 days.
- Known allergy to study device.
- History of confirmed or suspected heparin-induced thrombocytopenia.
- Inclusion in other study within the last 30 days.
- Pregnancy.
- Coexisting illness with a high probability of death (inferior to 6 months).

Study protocol

Randomisation

Patients will be randomised into two parallel open-label group. Randomisation will be carried out using Clinsight software, implemented by a data manager. The result of randomisation will be displayed as ‘standard group’ or ‘intervention group’ (figure 1).

Intervention

In the intervention group, cardiac surgery will be conducted with the use of the oXiris membrane connected to the CPB device.

The oXiris membrane will be fitted to a dedicated Prismaflex machine (Baxter, Illinois, USA) at the maximum flow rate recommended by the pharmaceutical laboratory at a blood flow rate of 450 mL/min (figure 2). The inflow of the Prismaflex (and the OXiris membrane) will be positioned between the venous line of CPB and the reservoir, and the outflow between the venous reservoir and the head of the CPB pump. In the standard group, cardiac surgery with CPB without the use of the oXiris membrane. The conditions for performing CPB are those usually used for this type of surgery in the Anesthesia Department of the Amiens University Hospital, and do not differ from those that would be used outside the scope of this study.

For both arms, monitoring of sublingual microcirculation, primary and secondary endpoints will be assessed as defined in the Data collection and outcome definitions section.

There is no provision for ancillary and post-trial care.

Standard procedures

Patients will undergo cardiac surgery as usual and usual postoperative care will be provided. CPB circuit will be primed (1000 mL crystalloid and 500 mL colloid solution together with 5000 IE heparin) in accordance with institutional guidelines. CPB will be performed by using non-pulsatile flow at 2.5 L/min/m², a non-heparin-coated circuit, and a membrane oxygenator (QuadroxTM, Maquet, Hirrlingen, Germany, or Capiox, Terumo, Eschborn, Germany). Blood transfusion will be performed in accordance with the Society of Thoracic Surgeons/Society of Cardiovascular Anesthesiologists (STS-SCA) transfusion guidelines and administration.
of coagulation factors will be based on blood samples. Blood samples and all variables will be equally collected and registered in the control group with no modifications from CPB standard practice. The conduct of CPB will be standardised for the study with normothermia, haematocrit more than 20%, mean arterial pressure over 50 mm Hg using vasopressor if required.

Standard of care will be given in the ICU after cardiac surgery to all study subjects. Especially for mechanical ventilation, nutrition, sedation, anticoagulation and blood glucose control, therapy is based on local treatment protocols. In the intensive care unit (ICU), treatment with vasopressors, inotropes and fluids is guided by haemodynamic monitoring using echocardiography to achieve a mean arterial pressure of 65 mm Hg, a cardiac index over 2.5 mL/min/m² and a diuresis >0.5 mL/kg/hour. All patient will have a continuous cardiac output monitoring with a transpulmonary thermodilution device (Picco, Drager). Haemodynamics timepoint assessment will be performed at ICU admission, 6 hours after, at day 1 and at day 2 after surgery.

**Outcome measures**

**Primary endpoint**

The endpoints and definitions are presented in table 1.

The primary endpoint will be the microcirculatory flow using the MFI measured by sublingual microcirculation device at day 1 following cardiac surgery. Sublingual microcirculation will be visualised and measured using an incident dark field imaging device (Cytocam, Breadius, Amsterdam, The Netherlands) derived from the orthogonal polarised spectral imaging. Five sequences of 20 s each from different adjacent sublingual areas will be recorded. Video sequences will be analysed offline by a single rater blinded to the timepoint of

---

**Figure 1** Consort diagram. CABG, coronary arterial bypass graft; CPB, cardiopulmonary bypass.

**Figure 2** Insertion of the Oxiris membrane within the cardiopulmonary bypass (CPB). The Oxiris membrane will be connected to the Prismaflex. The inflow of the Prismaflex (and the Oxiris membrane) will be positioned between the venous line of CPB and the reservoir, and the outflow between the venous reservoir and the head of the pump. Appendices: Informed consent given to participant and authorised surrogates.
Table 1  Endpoints and definitions

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary endpoint at day 1 after cardiac surgery</strong></td>
<td><strong>Microcirculatory flow index</strong> Microcirculatory flow index (MFI) measured by sublingual microcirculation device (Cytocam, Braedius Medical) at day 1 following cardiac surgery. A 20 s video sequence is recorded. A grid (four quadrants) of the measurement area is made and the predominant type of flow is analysed. The flux is noted from 0 (no flow) to 3 (continuous). The MFI is the average value of each the four quadrants, giving a total score from 0 to 3. The measurement is repeated for four sublingual areas.</td>
</tr>
<tr>
<td><strong>Secondary endpoints</strong></td>
<td><strong>Microcirculatory flow</strong> Before CPB, at the end of CPB and at 6, 24 and 48 hours postoperatively with the following items: ► MFI (microcirculatory flow index) ► PPV (proportion of perfused vessels) ► PVD (perfused vessel density) ► HI (heterogeneity index)</td>
</tr>
<tr>
<td></td>
<td><strong>Major cardiovascular and cerebral event (MACE)</strong> One of the following criterion (definitions above): ► Stroke ► Myocardial infarction ► Acute kidney injury ► Mesenteric ischaemia ► Successful resuscitated cardiac arrest</td>
</tr>
<tr>
<td></td>
<td><strong>Stroke</strong> An embolic, thrombotic or haemorrhagic cerebral event with persistent residual motor, sensory or cognitive dysfunction (eg, hemiplegia, hemiparesis, aphasia, sensory deficit, impaired memory) diagnosed on a cerebral scanner</td>
</tr>
<tr>
<td></td>
<td><strong>Myocardial infarction</strong> Myocardial infarction was diagnosed by the characteristics presentation, serial changes on 12-lead electrocardiographic suggesting infarction, and arise in cardiac markers, preferably cardiac troponins, with at least one value above the 99th percentile of the upper reference limit</td>
</tr>
<tr>
<td></td>
<td><strong>Acute kidney injury</strong> KDIGO guidelines Increase in serum creatinine of over 27 μmol/L within 48 hours or diuresis lower than 0.5 mL/kg/hour</td>
</tr>
<tr>
<td></td>
<td><strong>Mesenteric ischaemia</strong> Mesenteric ischaemia confirmed by imaging or exploratory laparotomy and/or ischaemic colitis confirmed by gastrointestinal endoscopy or exploratory laparotomy</td>
</tr>
<tr>
<td></td>
<td><strong>Resuscitated cardiac arrest</strong> Cessation of mechanical cardiac activity confirmed by the absence of clinical signs of blood flow</td>
</tr>
<tr>
<td></td>
<td><strong>In-hospital mortality</strong> Mortality from surgery to hospital discharge</td>
</tr>
<tr>
<td></td>
<td><strong>1-month hospital mortality</strong> Mortality after surgery until 1-month follow-up</td>
</tr>
<tr>
<td></td>
<td><strong>Cumulative catecholamine use</strong> Cumulative dose of norepinephrine and dobutamine in resuscitation during stay in mg</td>
</tr>
<tr>
<td></td>
<td><strong>SOFA score</strong> Sepsis Organ Failure Assessment</td>
</tr>
<tr>
<td></td>
<td><strong>SAPS II</strong> Simplified Acute Physiologic Score Assessment</td>
</tr>
<tr>
<td></td>
<td><strong>Biomarkers of glycocalyx degradation</strong> Before CPB, at the end of CPB then at 6, 24 and 48 hours postoperatively. ► Syndecan-1 ► Heparan-sulfate ► Hyaluronic acid Biomarkers will be assessed by ELISA test with dedicated kits.</td>
</tr>
<tr>
<td></td>
<td><strong>Biomarkers of endothelial permeability</strong> Before CPB, at the end of CPB then at 6, 24 and 48 hours postoperatively ► Angiopoietin 1 ► Angiopoietin 2 ► Soluble Tie2 receptor ► Vascular Endothelial Growth Factor (VEGF) Biomarkers will be assessed by ELISA test with dedicated kits.</td>
</tr>
<tr>
<td></td>
<td><strong>Pro and anti-inflammatory cytokine</strong> Before CPB, at the end of CPB then at 6, 24 and 48 hours postoperatively ► TNF alpha ► IL1 beta ► IL-10 ► IL-6 ► LPS ► Endothelin Biomarkers will be assessed by ELISA test with dedicated kits.</td>
</tr>
</tbody>
</table>

CPB, cardiopulmonary bypass; IL, interleukin; KDIGO, Kidney Disease Improving Global Outcomes; LPS, lipopolysaccharide; SAPS, Simplified Acute Physiologic Score; SOFA, Sepsis Organ Failure Assessment; TNF, tumour necrosis factor.
and hyaluronic acid), inflammation, calyx shedding markers (syndecan-1, heparan-sulfate), will be measured on blood sample. Endothelium glycocalyx shedding markers (angiopoietin 1, angiopoietin 2, Tie2 soluble receptor and VEGF) will be collected before CPB, at the end of CPB, 6 hours after ending CPB, then at day 1 and day 2 after CPB.

Endpoints will be assessed after cardiac surgery. Adverse events will be declared and notified in the electronic case report forms (eCRFs).

Some secondary endpoints cannot be measured blindly and may be influenced by the treatment group. An independent observer blinded from the treatment group will be in charge of collecting data. The primary outcome and biological data will be collected blinded to the treatment group.

Standard definitions of postoperative outcomes established by the European Society of Anaesthesia were used. Cardiac arrest is defined as the cessation of cardiac mechanical activity, as confirmed by the absence of circulation signs. Stroke is defined as an embolic, thrombotic or haemorrhagic cerebral event with persistent residual motor, sensory or cognitive dysfunction (e.g., hemiplegia, hemiparesis, aphasia, sensory deficit, impaired memory) diagnosed on a cerebral scanner. Acute kidney injury is defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria as an increase in serum creatinine of over 27 μmol/L within 48 hours or diuresis lower than 0.5 mL/kg/hour. Myocardial injury is diagnosed by the characteristics presentation, serial changes on 12-lead electrocardiographic suggesting infarction, and arise in cardiac troponin, with at least one value above the 99th percentile of the upper reference limit. Mesenteric ischaemia will be confirmed by imaging or exploratory laparotomy and ischaemic colitis will be confirmed by gastrointestinal endoscopy or exploratory laparotomy.

Data collection and outcome definitions
The following data will be collected: age (years), gender, body mass index (kg/m²), medical history (coronary disease, peripheral vascular disease, stroke, smoking, diabetes, dyslipidaemia, chronic obstructive pulmonary disease, logistic EuroSCORE, hypertension, chronic kidney disease, usual medication, surgery type (valve replacement, coronary bypass graft or combined surgery), preoperative left ventricular ejection fraction, baseline haemoglobin, duration of CPB and aortic clamp, intraoperative transfusion, and cumulative dose of vasoactive drugs (dobutamine, norepinephrine, ephedrine, phenylephrine).

Before and after CPB until day 2, the following data will be collected: systolic arterial pressure, diastolic arterial pressure, mean arterial pressure, heart rate, arterial blood gas variables (pH, PaO₂, PaCO₂, lactate, HCO₃⁻, ScvO₂ (%)), SOFA score, SAPS II score, vasoactive drug dose and biological variables (creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), prothrombin time (PT), platelet, cardiac troponin, myoglobin). ICU and hospital stays (days) will be recorded. Endothelium glycocalyx shedding markers (syndecan-1, heparan-sulfate and hyaluronic acid), inflammatory cytokine dosage (TNF alpha, IL1 beta, IL 10, IL 6, LPS, endothelin), and endothelial permeability biomarkers (angiopoietin 1, angiopoietin 2, Tie2 soluble receptor and VEGF) will be also evaluated.

Secondary endpoint
The secondary endpoints will be other microcirculatory flow variables: the perfused vessel density (PVD), the proportion of perfused vessels (PPV), the total vessel density and the De Backer score recorded by the sublingual microcirculation device (Cytocam, Breadius, Amsterdam, The Netherlands) and automatically calculated via a dedicated software (CytoCamtools software (Braedius Medical, Huizen, the Netherlands) at different timepoints; prior to CPB, at the end of CPB, 6 hours after CPB, at day 1 and at day 2.

We also aim to evaluate the occurrence within the first 30 days of major cardiovascular and cerebral events (MACE) defined as the occurrence of at least one outcome among the following: successfully resuscitated cardiac arrest, stroke, acute kidney injury, myocardial infarction, mesenteric ischaemia. Other outcomes will be in-hospital mortality and at 1 month, cumulative catecholamine use, ICU stay (days), hospital stay (days), Sepsis Organ Failure Assessment (SOFA) score and Simplified Acute Physiologic Score (SAPS) II. Several biomarkers will be measured on blood sample. Endothelium glycocalyx shedding markers (syndecan-1, heparan-sulfate and hyaluronic acid), inflammatory cytokines (tumour necrosis factor (TNF) alpha, interleukin 1 (IL1) beta, IL 10, IL 6, LPS) and endothelial permeability biomarkers (angiopoietin 1, angiopoietin 2, Tie2 soluble receptor, endothelin-1 and Vascular Endothelial Growth Factor (VEGF)) will be also evaluated.

Intention-to-treat analysis
Patients with serious adverse events will be analysed according to their assigned group following the intention-to-treat principle.

Statistical method and sample size calculation
According to a recent study, we predict a baseline mean MFI of 2.8 with an SD of 0.5.5

Admitting that the SD of MFI at D1 is 0.5 in both groups, we calculated a sample size of 70 patients to show a difference in MFI of 0.4 at D1 after surgery in a two-sided test with a type 1 error of 0.05 and a power of 90%. Approximately 450 cardiac surgery procedures with bypass surgery are performed per year at Amiens University Hospital. If we consider that 30% of patients will be eligible, this represents a potential inclusion of 130 patients per year. Taking into account possible non-inclusions due to
vacations and operating room closures, a total inclusion time of 7 months is expected for a total of 70 patients.

Thirty-five patients in each group (standard and interventional groups).

Primary endpoint will be compared by a Student’s test or Wilcoxon-Mann-Whitney test as appropriate. Secondary endpoints will be assessed using an analysis of variance test for repeated measures. MACE and mortality rate will be compared with a \( \chi^2 \) test. ICU and hospital stay will be compared using a Student’s test. Cumulative event curves will be estimated with the Kaplan-Meier procedure (censored at 30 days). Variables or parameters between usual and intervention groups will be compared with a Student’s test, a Wilcoxon-Mann-Whitney test, a \( \chi^2 \) or a Fisher’s exact test as appropriate. A p value of 0.05 will be considered as significant. No intermediate analysis is planned in the trial.

Data management and monitoring

Registration
Data will be collected and registered using eCRFs by a dedicated local research technician. A research coordinator will centralise and verify the data.

Record keeping
Consent forms and eCRFs will be retained for 15 years at the University Hospital of Amiens in accordance with French law.

Study organisation
The study promotion is performed by the University Hospital of Amiens, France.

Duration and timeline
Patients from the Amiens University Hospital can be included during a 2-year period beginning from July 2020.

The processes of developing the protocol, obtaining approval from the ethical committee, obtaining financial support and developing the eCRFs occurred in 2019. The database should be closed after all participants have been included, followed by data analysis, manuscript writing and submission for publication.

Ethics and dissemination

The Institutional Review Board (IRB) of the University Hospital of Amiens (Comité de Protection des Personnes Nord-Ouest III, 80 054 Amiens, France) approved the study (Registration number ID RDB: 2019-A02437-50 in February 2020). The Oxicard study will be conducted in accordance with the Declaration of Helsinki and French law on clinical research and was registered on 17 February 2020. The Oxicard study includes the implementation of the CONSORT statement—CONSORT diagram is given in figure 1.\(^\text{19}\) Written informed consent will be obtained from all participants or next of kin.

Authors will be involved in disseminating research findings (through attending conferences and coauthoring results’ papers).

Patients or public involvement
Patients or the public will not be involved in the design, or conduct, or reporting or dissemination plans of our research. Written informed consent will be obtained from all participants or next of kin.

DISCUSSION

The hypothesis is that early use (during CPB) of cytokine adsorption with the oXiris membrane in patients at high risk of vasoplastic syndrome following cardiac surgery may improve microcirculation and endothelial function.

Postoperative period following cardiac surgery is associated with an inflammatory state leading to side effects such as vasoplegia and major adverse events.\(^\text{20}\) Clinical and experimental data support a link between inflammation with cytokine production and endothelial cell injury.\(^\text{21}\) Microcirculatory impairment has also been observed after cardiac surgery.\(^\text{22}\)\(^\text{23}\)

Despite normal macrocirculatory variables, microcirculatory dysfunction resulting in functional oxygen shunting can lead to impairment in oxygen delivery and thus to organ dysfunction and mortality.\(^\text{24}\)

Several studies have investigated cytokine adsorption in vitro. Moreover, it has been shown that oXiris membrane reduces the concentration of cytokines after CPB and during sepsis.\(^\text{9}\)\(^\text{10}\) However, to date, no studies have been performed on the effect of cytokine adsorption on endothelial function and microcirculation.

We hypothesise that systemic microcirculation, assessed by sublingual microcirculation, may be improved when an adsorbent membrane is used to reduce the amount of circulating cytokines.

A pilot study to evaluate the cytokine adsorption effect is an important step before carrying out a larger prospective randomised study with clinical endpoints.

Nevertheless, we will also assess MACE (stroke, acute kidney injury and myocardial infarction) in order to evaluate the impact of improved microcirculation on organ dysfunction. In the event of a positive effect, a multicentre randomised trial will be conducted using morbidity and mortality as primary endpoints.

We have privileged sublingual microcirculatory measurement at day 1 as a primary endpoint. Measurement at H6 may be difficult when the patient is awakening. Six hours after the end of CPB, some patients may still be under sedation and some may not. We will adjust the results on the patient’s state of awakening in order to avoid measurement bias.

Trial status
The trial is not yet recruiting.

Acknowledgements The Oxiris trial is sponsored by Amiens Hospital University.
REFERENCES